课题基金 / 基金详情

LANREOTIDE (IPSTYL) IN " DENOVO" ACROMEGALICS

LANREOTIDE (IPSTYL) IN " DENOVO" ACROMEGALICS
“DENOVO”ACROMEGALICS 中的兰瑞肽 (IPSTYL)
批准号：
6264598
负责人：
DAVID L KLEINBERG
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264598
关键词：
acromegaly clinical research drug screening /evaluation endocrine disorder chemotherapy hormone therapy human subject human therapy evaluation insulinlike growth factor neoplasm /cancer chemotherapy peptide hormone analog somatostatin somatotropin

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
这一开放标签的非随机方案的目的是研究生长抑素的合成类似物兰瑞肽(IPSTYL)治疗肢端肥大症的安全性和有效性。受试者将接受长达四个月的药物治疗。GH和IGF-1水平的正常化将用于确定疗效。次要目标将是从肿瘤大小、症状、不良事件以及在无法恢复正常的情况下将生长激素水平降低到5 ng/ml方面来研究兰克利肽的安全性和有效性。
英文摘要
The objectives of this open label, non-randomized protocol are to investigate the safety and efficacy of lanreotide (IPSTYL), a synthetic analogue of somatostatin, in the treatment of acromegaly. Subjects will receive drug up to four months. Normalization of GH and IGF-1 levels will be used to determine efficacy. Secondary objectives will be to investigate the safety and efficacy of lancreotide with respect to tumor size, symptoms, adverse events, and reduction of GH levels to < 5ng/ml if normalization is not possible.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金